Daniel Cui Zhou
Overview
Explore the profile of Daniel Cui Zhou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
2870
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zhou D, Jayasinghe R, Chen S, Herndon J, Iglesia M, Navale P, et al.
Nat Genet
. 2022 Aug;
54(9):1390-1405.
PMID: 35995947
Pancreatic ductal adenocarcinoma is a lethal disease with limited treatment options and poor survival. We studied 83 spatial samples from 31 patients (11 treatment-naïve and 20 treated) using single-cell/nucleus RNA...
12.
Storrs E, Zhou D, Wendl M, Wyczalkowski M, Karpova A, Wang L, et al.
Bioinform Adv
. 2022 May;
2(1):vbac028.
PMID: 35603231
Motivation: The use of single-cell methods is expanding at an ever-increasing rate. While there are established algorithms that address cell classification, they are limited in terms of cross platform compatibility,...
13.
Cao L, Huang C, Zhou D, Hu Y, Lih T, Savage S, et al.
Cell
. 2021 Sep;
184(19):5031-5052.e26.
PMID: 34534465
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient survival. Toward understanding the underlying molecular alterations that drive PDAC oncogenesis, we conducted comprehensive proteogenomic analysis of 140...
14.
Huang K, Scott A, Zhou D, Wang L, Weerasinghe A, Elmas A, et al.
Nat Commun
. 2021 Apr;
12(1):2313.
PMID: 33875650
Advances in mass-spectrometry have generated increasingly large-scale proteomics datasets containing tens of thousands of phosphorylation sites (phosphosites) that require prioritization. We develop a bioinformatics tool called HotPho and systematically discover...
15.
Wang L, Karpova A, Gritsenko M, Kyle J, Cao S, Li Y, et al.
Cancer Cell
. 2021 Feb;
39(4):509-528.e20.
PMID: 33577785
Glioblastoma (GBM) is the most aggressive nervous system cancer. Understanding its molecular pathogenesis is crucial to improving diagnosis and treatment. Integrated analysis of genomic, proteomic, post-translational modification and metabolomic data...
16.
Han X, Zhang S, Zhou D, Wang D, He X, Yuan D, et al.
Brief Bioinform
. 2021 Jan;
22(5).
PMID: 33461213
Motivation: Microsatellite instability (MSI) is a promising biomarker for cancer prognosis and chemosensitivity. Techniques are rapidly evolving for the detection of MSI from tumor-normal paired or tumor-only sequencing data. However,...
17.
Huang C, Chen L, Savage S, Eguez R, Dou Y, Li Y, et al.
Cancer Cell
. 2021 Jan;
39(3):361-379.e16.
PMID: 33417831
We present a proteogenomic study of 108 human papilloma virus (HPV)-negative head and neck squamous cell carcinomas (HNSCCs). Proteomic analysis systematically catalogs HNSCC-associated proteins and phosphosites, prioritizes copy number drivers,...
18.
Cao S, Zhou D, Oh C, Jayasinghe R, Zhao Y, Yoon C, et al.
Nat Commun
. 2020 Nov;
11(1):5573.
PMID: 33149122
Non-coding mutations can create splice sites, however the true extent of how such somatic non-coding mutations affect RNA splicing are largely unexplored. Here we use the MiSplice pipeline to analyze...
19.
Dou Y, Kawaler E, Zhou D, Gritsenko M, Huang C, Blumenberg L, et al.
Cell
. 2020 Feb;
180(4):729-748.e26.
PMID: 32059776
We undertook a comprehensive proteogenomic characterization of 95 prospectively collected endometrial carcinomas, comprising 83 endometrioid and 12 serous tumors. This analysis revealed possible new consequences of perturbations to the p53...
20.
Bailey M, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, et al.
Cell
. 2018 Aug;
174(4):1034-1035.
PMID: 30096302
No abstract available.